Search research articles
Contact Us
Filters
Showing results (91-100 of 100) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 100 results.
Actas Urologicas Espanolas
|
March 17, 2025
Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients
M Hassi Roman, K Mate, P de Pablos-RodrIguez, et al.
The New England Journal of Medicine
|
December 16, 2014
Adjuvant ovarian suppression in premenopausal breast cancer
Prudence A Francis, Meredith M Regan, Gini F Fleming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
The Prostate
|
December 24, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
María P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Clinical Genitourinary Cancer
|
January 7, 2023
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
Guillermo de Velasco, Teresa Alonso-Gordoa, Alejo Rodríguez-Vida, et al.
The New England Journal of Medicine
|
June 5, 2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Prudence A Francis, Olivia Pagani, Gini F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
P A Francis, O Pagani, G F Fleming, et al.
BMC Cancer
|
February 25, 2016
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
Nuria Lainez, Jesús García-Donas, Emilio Esteban, et al.
Clinical Genitourinary Cancer
|
November 18, 2021
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Álvaro Pinto, Oscar Reig, Clara Iglesias, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 100) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 100 results.
Actas Urologicas Espanolas
|
March 17, 2025
Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients
M Hassi Roman, K Mate, P de Pablos-RodrIguez, et al.
The New England Journal of Medicine
|
December 16, 2014
Adjuvant ovarian suppression in premenopausal breast cancer
Prudence A Francis, Meredith M Regan, Gini F Fleming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
The Prostate
|
December 24, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
María P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Clinical Genitourinary Cancer
|
January 7, 2023
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
Guillermo de Velasco, Teresa Alonso-Gordoa, Alejo Rodríguez-Vida, et al.
The New England Journal of Medicine
|
June 5, 2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Prudence A Francis, Olivia Pagani, Gini F Fleming, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
P A Francis, O Pagani, G F Fleming, et al.
BMC Cancer
|
February 25, 2016
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
Nuria Lainez, Jesús García-Donas, Emilio Esteban, et al.
Clinical Genitourinary Cancer
|
November 18, 2021
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Álvaro Pinto, Oscar Reig, Clara Iglesias, et al.
Page
of 10